National Service Hotline:

13357226518

current location: Home > News Center > Company News
Company News

New drug research and development to promote biotechnology companies become a hot acquisition target

author: source: Xinhua health time:2016 08 29
  Tencent finance and economics news Beijing time on July 14 morning news, at present, to focus on R & D put in cancer treatment drugs, biotechnology company tends to become the pharmaceutical industry the most popular target for a takeover, with the advent of all kinds of new drugs, these companies also continue to add value. In addition, there are a number of research and development of immune and neurological disorders drugs companies have become the target of acquisition.

  According to investment bankers and industry sources, global mergers and acquisitions (M & A) the impact of speculation in the wind, biotechnology companies have a higher valuation, some enterprises can even to intention to purchase request premium of up to 30% to 40%. "We have seen some very successful treatment of cancer drugs, at present the market needs new drugs," said hedge fund DAFNA capital of the chief investment Fareed Reba - Godesin Fariba Ghodsian. (Yi Hai)
Share to:
Contact Us

13357226518

hotline

Map At the foot of the valley Yuyuan C3 building 1103 room
Contact us

National Service Hotline:

13357226518
  HunanHuiBaiShiBiotechnologyCo,Ltd
  Tel:+86-13319518603
  +86-13308453923
  +86-0731-85525605
  QQ:3002724707
  Fax:0731-85525705
  E-mail:hbs5509@hnhbsbio.com
  Website:www.hnhbsbio.com
  Skype:cielchen@hnhbsbio.com
  Address:HunanprovinceChangshaWenxuanhightechDevelopmentZone,RoadNo.27LuValleyYuyuanC3building1103room
Web site keywords
antibiotic buffer solution other reagent yield a product